Sunday, 17 October 2021

WuXi Biologics completed three acquisitions to enhance its global network

07 May 2021 | News

Acquires Bayer in Germany, Pfizer China, and CMAB Biopharma Group in China to expand total of 33 DS and DP facilities planned in five countries globally

Photo Credit: Freepik

Photo Credit: Freepik

WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal, Germany, the Pfizer China ("Pfizer") manufacturing facilities in Hangzhou, China as well as CMAB Biopharma Group ("CMAB").

Under the acquisition agreement signed in December 2020 with Bayer, WuXi Biologics took over the operations and assets of a Drug Substance facility (MFG19) located in Wuppertal, Germany that will include 3 x 1,000L perfusion and 6 x 2,000L fed-batch capacity with independent downstream suites. Announced in March 2021, WuXi Biologics closed the acquisition of biologics drug substance and product facilities (MFG20/DP9/DP10) from Pfizer China located in Hangzhou with 2 x 2,000L single-use bioreactors that can be expanded to 4 x 2,000L. The site also contains two state-of-the-art Drug Product (DP) manufacturing facilities, for drug product formulation and filling in vials and syringes.

The acquisition of CMAB, a biologics Contract Development and Manufacturing Organization (CDMO) with operations in Suzhou, China, was also announced in March 2021. The CDMO operations maintain facilities (MFG21/DP11) with 7,000 liters bioreactor DS capacity as well as DP manufacturing for both liquid and lyophilization fills. WuXi Biologics acquired 100% interest of CMAB, which will be renamed as WuXi Biologics (Suzhou) and operate as a wholly-owned subsidiary.

All these acquired facilities are expected to be ready for GMP manufacturing in 2021 and enhance global footprints at WuXi Biologics. With these expansions, the total capacity of the company's 11 DS facilities in China, the U.S. and Germany will be increased to 150,000 liters by the end of 2021. In addition, there will be nine GMP DP facilities for vials and syringes in China, the U.S. and Germany to meet all clients' needs this year.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We're excited to complete these significant deals with Bayer, Pfizer and CBC Group and are glad to welcome the highly skilled talents to our WuXi Biologics family. In the past decade, we have continued to expand our capacities and capabilities to build a global biologics network while also strengthening the local supply chain to meet the growing outsourcing demands for biologics. With total 33 DS and DP facilities planned in five countries globally, we will continue to manufacture high-quality biologics and deliver them in a timely manner through our robust manufacturing capacity and resilient supply chains for the benefits of patients worldwide."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account